U.S. Cell and Gene Therapy Clinical Trial Services Market Size, Share & Trends Analysis Report by Service (Site Identification, Patient Recruitment), Phase (Phase I, Phase II), Therapeutic Areas, Therapy Type, and Segment Forecasts, 2024-2030

1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.1.2. Service
1.1.3. Phase
1.1.4. Therapeutic Areas
1.1.5. Therapy Type
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. List Of Secondary Sources
1.11. List Of Abbreviations

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Investments and R&D Funding for the Development of Cell and Gene Therapeutics
3.2.1.2. Growing Adoption of Novel Technologies in Clinical Research and Supply Chain
3.2.1.3. Increasing Mergers & Acquisitions in the Cell and Gene Therapy Industry
3.2.2. Market Restraint Analysis
3.2.2.1. Obstacles in Patient Recruitment and Retention
3.2.2.2. Stringent Regulations Pertaining to Clinical Trial Design and Logistics
3.3. U.S. Cell and Gene Therapy Clinical Trial Services Market Analysis Tools
3.3.1. Service Analysis - Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat Of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.4. Clinical Trial Supply & Logistics Industry: Impact of COVID -19
3.4.1. Impact Of COVID-19
3.4.2. Supply Chain
3.4.3. Changing Market Trends
3.5. Logistics Challenges
3.5.1. Novel Services Offered in the Clinical Trial Supply & Logistics Field to Overcome the Challenges Associated With Supply Chain Logistics
3.5.1.1. Incorporation of Novel Technology
3.5.1.2. Advancements in Storage Technology
3.5.1.3. Mode of Distribution Analysis
3.5.1.4. Clinical Trial Supply Chain
3.6. Cell & Gene Therapy Clinical Trials Volume Analysis (2020 - 2022)
3.6.1. Global CGT Trial Volume from 2020 to 2022
3.6.1.1. Region-wise CGT Trial Volume, 2022
3.6.1.2. Major Country Share (%) in CGT Trials, 2022
3.6.1.3. By Study Design Share (%) in CGT Trials, 2022
3.6.1.4. By Indication Share (%) in CGT Trials, 2022
3.7. Regulatory Framework
3.7.1. U.S.
3.7.2. Europe
3.7.3. China
3.7.3.1. Regulatory challenges & risk of selling unapproved cell therapies
3.7.4. Japan

4.1. U.S. Cell and Gene Therapy Clinical Trial Services Market, By Service: Segment Dashboard
4.2. U.S. Cell and Gene Therapy Clinical Trial Services Market, By Service: Movement Analysis
4.3. U.S. Cell and Gene Therapy Clinical Trial Services Market Estimates & Forecasts, By Service, 2018 - 2030
4.3.1. Site Identifications
4.3.1.1. Site Identification U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)
4.3.2. Patient Recruitments
4.3.2.1. Patient Recruitments U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)
4.3.3. Laboratory Services
4.3.3.1. Laboratory Services U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)
4.3.4. Regulatory Services
4.3.4.1. Regulatory Services U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)
4.3.5. Supply and Logistic Services
4.3.5.1. Supply and Logistic Services U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)
4.3.5.2. Logistics & Distribution
4.3.5.2.1. Logistics & Distribution U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)
4.3.5.3. Storage & Retention
4.3.5.3.1. Storage & Retention U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)
4.3.5.4. Packaging, Labeling, And Blinding
4.3.5.4.1. Packaging, Labeling, And Blinding U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)
4.3.5.5. Manufacturing
4.3.5.5.1. Manufacturing U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)
4.3.5.6. Comparator Sourcing
4.3.5.6.1. Comparator Sourcing U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)
4.3.5.7. Regulatory and customs support
4.3.5.7.1. Regulatory and Customs Support U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)
4.3.5.8. Other Services
4.3.5.8.1. Other Services U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)
4.3.6. Others
4.3.6.1. Others U.S. Cell and Gene Therapy Clinical Trial Services Market, 2018 to 2030 (USD Million)

5.1. U.S. Cell and Gene Therapy Clinical Trial Services Market, By Phase: Segment Dashboard
5.2. U.S. Cell and Gene Therapy Clinical Trial Services Market, By Phase: Movement Analysis
5.3. U.S. Cell and Gene Therapy Clinical Trial Services Market Estimates & Forecasts, By Phase, 2018 - 2030
5.3.1. Phase I
5.3.1.1. Phase I U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
5.3.2. Phase II
5.3.2.1. Phase II U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
5.3.3. Phase III
5.3.3.1. Phase III U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
5.3.4. Phase IV
5.3.4.1. Phase IV U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)

6.1. U.S. Cell and Gene Therapy Clinical Trial Services Market, By Therapeutic Areas: Segment Dashboard
6.2. U.S. Cell and Gene Therapy Clinical Trial Services Market, By Therapeutic Areas: Movement Analysis
6.3. U.S. Cell and Gene Therapy Clinical Trial Services Market Estimates & Forecasts, By Therapeutic Areas, 2018 - 2030
6.3.1. Oncology
6.3.1.1. Oncology U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
6.3.2. Central Nervous System (CNS) Disorders
6.3.2.1. Central Nervous System (CNS) Disorders U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
6.3.3. Cardiovascular Diseases
6.3.3.1. Cardiovascular Diseases U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
6.3.4. Infectious Diseases
6.3.4.1. Infectious Diseases U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
6.3.5. Musculoskeletal
6.3.5.1. Musculoskeletal U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
6.3.6. Others
6.3.6.1. Others U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)

7.1. U.S. Cell and Gene Therapy Clinical Trial Services Market, By Therapy Type: Segment Dashboard
7.2. U.S. Cell and Gene Therapy Clinical Trial Services Market, By Therapy Type: Movement Analysis
7.3. U.S. Cell and Gene Therapy Clinical Trial Services Market Estimates & Forecasts, By Therapy Type, 2018 - 2030
7.3.1. Gene Therapy
7.3.1.1. Gene Therapy U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
7.3.2. Gene-Modified Cell Therapy
7.3.2.1. Gene-Modified Cell Therapy U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
7.3.2.2. CAR T-cell therapies
7.3.2.2.1. CAR T-cell therapies U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
7.3.2.3. CAR-NK cell therapy
7.3.2.3.1. CAR-NK cell therapy U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
7.3.2.4. TCR-T cell therapy
7.3.2.4.1. TCR-T cell therapy U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
7.3.2.5. Others
7.3.2.5.1. Others U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)
7.3.3. Cell Therapy
7.3.3.1. Cell Therapy U.S. Cell and Gene Therapy Clinical Trial Services Market 2018 to 2030 (USD Million)

8.1. Company Categorization
8.1.1. By CROs
8.1.2. By CGT Supply/Logistics Providers
8.1.3. Service Heat Map Analysis
8.1.3.1. By CGT Sponsor Companies
8.1.3.2. By CGT Supply/Logistics Providers
8.1.4. Global Company Market Share Analysis, 2023
8.2. Company Profiles (By CGT Clinical Trial Sponsors)
8.2.1. Novartis AG
8.2.1.1. Company Overview
8.2.1.2. Financial Performance
8.2.1.3. Service Benchmarking
8.2.1.4. Strategic Initiatives
8.2.2. Takeda Pharmaceutical Company Limited.
8.2.2.1. Company Overview
8.2.2.2. Financial Performance
8.2.2.3. Service Benchmarking
8.2.2.4. Strategic Initiatives
8.2.3. Gilead Sciences, Inc.
8.2.3.1. Company Overview
8.2.3.2. Financial Performance
8.2.3.3. Service Benchmarking
8.2.3.4. Strategic Initiatives
8.2.4. Amgen Inc.
8.2.4.1. Company Overview
8.2.4.2. Financial Performance
8.2.4.3. Service Benchmarking
8.2.4.4. Strategic Initiatives
8.2.5. bluebird bio, Inc.
8.2.5.1. Company Overview
8.2.5.2. Financial Performance
8.2.5.3. Service Benchmarking
8.2.5.4. Strategic Initiatives
8.2.6. Regeneron Pharmaceuticals Inc.
8.2.6.1. Company Overview
8.2.6.2. Financial Performance
8.2.6.3. Service Benchmarking
8.2.6.4. Strategic Initiatives
8.2.7. CRISPR Therapeutics
8.2.7.1. Company Overview
8.2.7.2. Financial Performance
8.2.7.3. Service Benchmarking
8.2.7.4. Strategic Initiatives
8.2.8. Pfizer
8.2.8.1. Company Overview
8.2.8.2. Financial Performance
8.2.8.3. Service Benchmarking
8.2.8.4. Strategic Initiatives
8.3. Company Profiles (By CGT Supply/Logistics Providers)
8.3.1. Biocair
8.3.1.1. Company Overview
8.3.1.2. Financial Performance
8.3.1.3. Service Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Modality Solutions LLC
8.3.2.1. Company Overview
8.3.2.2. Financial Performance
8.3.2.3. Service Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. BioLife Solutions, Inc.
8.3.3.1. Company Overview
8.3.3.2. Financial Performance
8.3.3.3. Service Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Marken
8.3.4.1. Company Overview
8.3.4.2. Financial Performance
8.3.4.3. Service Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Yourway
8.3.5.1. Company Overview
8.3.5.2. Financial Performance
8.3.5.3. Service Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Almac Group
8.3.6.1. Company Overview
8.3.6.2. Financial Performance
8.3.6.3. Service Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. Catalent, Inc
8.3.7.1. Company Overview
8.3.7.2. Financial Performance
8.3.7.3. Service Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Quick International Courier (QuickStat (Kuehne + Nagel Company)
8.3.8.1. Company Overview
8.3.8.2. Financial Performance
8.3.8.3. Service Benchmarking
8.3.8.4. Strategic Initiatives

Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 U.S. Cell and Gene Therapy Clinical Trial Services market, by Service, 2018 - 2030 (USD Million)
Table 4 U.S. Cell and Gene Therapy Clinical Trial Services market, by Supply and Logistic Services, 2018 - 2030 (USD Million)
Table 5 U.S. Cell and Gene Therapy Clinical Trial Services market, by Phase, 2018 - 2030 (USD Million)
Table 6 U.S. Cell and Gene Therapy Clinical Trial Services market, by Therapeutic Areas, 2018 - 2030 (USD Million)
Table 7 U.S. Cell and Gene Therapy Clinical Trial Services market, by Therapy Type, 2018 - 2030 (USD Million)
Table 8 U.S. Cell and Gene Therapy Clinical Trial Services market, by Gene-Modified Cell Therapy, 2018 - 2030 (USD Million)
Table 9 Company profiles: Company overview
Table 10 Company profiles: Financial performance
Table 11 Company profiles: Service benchmarking
Table 12 Key company initiating service launches/upgrades.
Table 13 Key companies initiating mergers/acquisitions/joint ventures.
Table 14 Key companies initiating a partnership.
Table 15 Key companies initiating expansion.
Table 16 Key companies initiating others.

Fig. 1 U.S. cell and gene therapy clinical trial services market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Data Analysis Models
Fig. 6 Market Formulation and Validation
Fig. 7 Data Validating & Publishing
Fig. 8 Parent market analysis
Fig. 9 Service/Commodity Flow Analysis
Fig. 10 Value-Chain-Based Sizing & Forecasting
Fig. 11 QFD model sizing & forecasting
Fig. 12 Market formulation & validation
Fig. 13 Market snapshot
Fig. 14 Segment snapshot
Fig. 15 Segment snapshot
Fig. 16 Competitive landscape snapshot
Fig. 17 Parent market outlook, 2023 (USD Million)
Fig. 18 Ancillary market outlook, 2023 (USD Million)
Fig. 19 U.S. cell and gene therapy clinical trial services market dynamics
Fig. 20 U.S. anticipated regulatory decisions in 2023
Fig. 21 M&A activity in the cell and gene therapy industry rose sharply in 2019
Fig. 22 Porter’s five forces analysis
Fig. 23 U.S. Cell and Gene Therapy Clinical Trial Services market: PESTEL analysis
Fig. 24 The challenge of CGT logistics
Fig. 25 Storage and/or shipping conditions of some cell therapy products
Fig. 26 The challenge of CGT logistics
Fig. 27 Distribution models
Fig. 28 Clinical trial supply chain
Fig. 29 Global CGT trial volume from 2020 to 2022
Fig. 30 Region-wise CGT trial volume, 2022
Fig. 31 Major Country Share (%) in CGT Trials, 2022
Fig. 32 By Study Design Share (%) in CGT Trials, 2022
Fig. 33 By Indication Share (%) in CGT Trials, 2022
Fig. 34 U.S. Cell and Gene Therapy Clinical Trial Services market: Service outlook and key takeaways
Fig. 35 U.S. Cell and Gene Therapy Clinical Trial Services market: Service movement analysis
Fig. 36 U.S. site identification market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 U.S. patient recruitment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 U.S. laboratory services market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 U.S. regulatory services market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 U.S. supply and logistic services market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 U.S. logistics & distribution market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 U.S. storage & retention market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 U.S. packaging, labeling, and blinding market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 U.S. manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 U.S. comparator sourcing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 U.S. regulatory and customs support market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 U.S. other services market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 U.S. others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 U.S. Cell and Gene Therapy Clinical Trial Services market: phase outlook and key takeaways
Fig. 50 U.S. Cell and Gene Therapy Clinical Trial Services market: phase movement analysis
Fig. 51 U.S. phase I market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 U.S. phase II market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 U.S. phase III market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 U.S. phase IV market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 U.S. Cell and Gene Therapy Clinical Trial Services market: Therapeutic areas outlook and key takeaways
Fig. 56 U.S. Cell and Gene Therapy Clinical Trial Services market: Therapeutic areas movement analysis
Fig. 57 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Central Nervous System (CNS) disorders market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Musculoskeletal market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 U.S. Cell and Gene Therapy Clinical Trial Services market: Therapy type outlook and key takeaways
Fig. 64 U.S. Cell and Gene Therapy Clinical Trial Services market: Therapy type movement analysis
Fig. 65 Gene therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Gene-modified cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 CAR T-cell therapies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 CAR-NK cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 TCR-T cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Key company categorization
Fig. 73 Key company categorization
Fig. 74 Service heat map analysis (CGT clinical trial companies/sponsors)
Fig. 75 Service heat map analysis (CGT supply/logistics providers)
Fig. 76 Global cell and gene therapy clinical trial services market share analysis, 2022 (By CGT trial sponsor companies)